Aromatase inhibitors adjuvant endocrine therapy post-menopausal receptor-positive early breast cancer

Recommendations for aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer. This document supplements guideline recommendation 19 about the use of tamoxifen for the management of post-menopausal women with hormone receptor-positive early breast cancer contained in the National Breast Cancer Centre** 'Clinical Practice Guidelines for the Management of Early Breast Cancer', 2nd edition, 2001 (page 9). ** In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

File name:
File size: 207563
Cancer Type:
Breast cancer
Publication Audience:
Resources for health professionals
Year: 2006
Document Status:
Greater than 5 years. This resource was developed, reviewed or revised more than 5 years ago and may no longer reflect current evidence or best practice.